These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11966509)

  • 41. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
    Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
    Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of alosetron on the pharmacokinetics of fluoxetine.
    D'Souza DL; Dimmitt DC; Robbins DK; Nezamis J; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):455-8. PubMed ID: 11304903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
    Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New therapeutic approaches in irritable bowel syndrome].
    Müller-Lissner SA
    Z Gastroenterol; 2000 Sep; 38(9):815-6. PubMed ID: 11072681
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
    Bush TG; Spencer NJ; Watters N; Sanders KM; Smith TK
    Am J Physiol Gastrointest Liver Physiol; 2001 Oct; 281(4):G974-83. PubMed ID: 11557518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ischemic colitis during treatment with alosetron.
    Friedel D; Thomas R; Fisher RS
    Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.
    Hammer J; Phillips SF; Talley NJ; Camilleri M
    Aliment Pharmacol Ther; 1993 Oct; 7(5):543-51. PubMed ID: 8280823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
    MMW Fortschr Med; 2000 Sep; 142(37):55. PubMed ID: 11026224
    [No Abstract]   [Full Text] [Related]  

  • 50. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
    Andresen V; Hollerbach S
    Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. So what happened to alosetron?
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
    [No Abstract]   [Full Text] [Related]  

  • 54. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S; Camilleri M; Linker Nord SJ; Burton DD; Castenada L; Croop R; Tong G; Dockens R; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1299-306. PubMed ID: 19342506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
    Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K; Mori T; Fu L; Ito T; Niisato T; Yoshida S; Shiokawa S; Sato Y; Murakami H; Shishikura T
    Neurogastroenterol Motil; 2005 Apr; 17(2):290-301. PubMed ID: 15787949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.
    Noor N; Small PK; Loudon MA; Hau C; Campbell FC
    Scand J Gastroenterol; 1998 Jun; 33(6):605-11. PubMed ID: 9669632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea.
    Chey WY; Jin HO; Lee MH; Sun SW; Lee KY
    Am J Gastroenterol; 2001 May; 96(5):1499-506. PubMed ID: 11374689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.